# Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer

> **NCT02562365** · PHASE2 · UNKNOWN · sponsor: **Xiaohua Wu MD** · enrollment: 130 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Etoposide, Cyclophosphamide, Carboplatin

## Key facts

- **NCT ID:** NCT02562365
- **Lead sponsor:** Xiaohua Wu MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2023-11
- **Final completion:** 2023-11
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562365, "Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02562365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*